UK markets close in 2 hours 45 minutes

ImmunoCellular Therapeutics, Ltd. (IMUC)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.18300.0000 (0.00%)
As of 12:13PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 20.73M
Enterprise value 20.73M
Trailing P/E 0.02
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.35
Enterprise value/revenue N/A
Enterprise value/EBITDA -3.67

Trading information

Stock price history

Beta (5Y monthly) 1.38
52-week change 3-49.17%
S&P500 52-week change 329.57%
52-week high 30.4000
52-week low 30.1510
50-day moving average 30.2904
200-day moving average 30.2921

Share statistics

Avg vol (3-month) 32.7k
Avg vol (10-day) 38.04k
Shares outstanding 5113.27M
Implied shares outstanding 6113.27M
Float 85.7M
% held by insiders 194.97%
% held by institutions 10.00%
Shares short (15 Oct 2018) 4165.95k
Short ratio (15 Oct 2018) 44.13
Short % of float (15 Oct 2018) 43.96%
Short % of shares outstanding (15 Oct 2018) 43.96%
Shares short (prior month 14 Sept 2018) 4147.78k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 316 Sept 2020
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 316 Sept 2020

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)30 Sept 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-440.45%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-5.13M
Diluted EPS (ttm)10.1700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)551.18k
Total cash per share (mrq)0
Total debt (mrq)3.05M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.97
Book value per share (mrq)-0.03

Cash flow statement

Operating cash flow (ttm)-2.79M
Levered free cash flow (ttm)-1.99M